Aviel Gal, Meirovitz Amichay, Planer David, Cohen Dotan, Gilon Dan, Feldman Jon, Shapira Oz M
Department of Cardiothoracic Surgery, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
Department of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
J Contemp Brachytherapy. 2019 Dec;11(6):579-583. doi: 10.5114/jcb.2019.91226. Epub 2019 Dec 25.
Primary sarcoma of the heart is a rare but devastating tumor. Median survival with conventional treatment is 8-12 months. When resection is not feasible, patients often succumb to heart failure secondary to obstruction of blood flow, valve dysfunction, chamber compression or conduction abnormalities. Palliative treatment options include systemic chemotherapy and external beam irradiation. We herein describe a novel technique using endovascular brachytherapy, aiming at reducing tumor mass, alleviating right ventricular pressure overload and at the same time keeping the option of R0 resection viable.
A 35-year-old man was diagnosed with a non-resectable high-grade intimal sarcoma of the right ventricle (RV), main pulmonary artery (PA) and right PA. After three cycles of doxorubicin and ifosfamide, the patient's symptoms of right heart failure worsened. Imaging documented tumor progression and supra-systemic pulmonary artery pressure. Through a trans-femoral venous access, a brachytherapy sleeve was placed in the RV and main and right PA. A dose of 20 Gy was delivered over a period of ten minutes.
The patient had an uneventful course and was discharged home 24 hours after the procedure. Ten months after brachytherapy, repeat imaging demonstrated a significant reduction in tumor volume and an increase in pulmonary artery cross-sectional area with a marked reduction of pulmonary artery pressure, leading to a complete resolution of heart failure symptoms.
Endovascular brachytherapy is a novel, safe and effective therapeutic modality for non-resectable primary cardiac sarcomas either for palliation of obstruction, or tumor mass reduction to allow complete resection.
原发性心脏肉瘤是一种罕见但极具破坏性的肿瘤。传统治疗的中位生存期为8 - 12个月。当无法进行切除时,患者常因血流阻塞、瓣膜功能障碍、心腔受压或传导异常继发心力衰竭而死亡。姑息治疗选择包括全身化疗和外照射。我们在此描述一种使用血管内近距离放疗的新技术,旨在减少肿瘤体积,减轻右心室压力过载,同时保持R0切除的可能性。
一名35岁男性被诊断为右心室(RV)、主肺动脉(PA)和右肺动脉不可切除的高级别内膜肉瘤。在接受三个周期的阿霉素和异环磷酰胺治疗后,患者右心衰竭症状加重。影像学检查记录了肿瘤进展和超系统性肺动脉压。通过经股静脉通路,将一个近距离放疗套管置于右心室、主肺动脉和右肺动脉。在十分钟内给予20 Gy的剂量。
患者术后过程顺利,术后24小时出院。近距离放疗十个月后,重复影像学检查显示肿瘤体积显著减小,肺动脉横截面积增加,肺动脉压明显降低,心力衰竭症状完全缓解。
血管内近距离放疗是一种新型、安全且有效的治疗方式,可用于不可切除的原发性心脏肉瘤,用于缓解阻塞或减少肿瘤体积以允许完整切除。